![714PPhase I study of the oncolytic viral immunotherapy agent canerpaturev (C-REV) with S-1 in patients with stage IV pancreatic cancer]()
714PPhase I study of the oncolytic viral immunotherapy agent canerpaturev (C-REV) with S-1 in patients with stage IV pancreatic cancerHijioka, S; Ueno, M; Ioka, T; Hirooka, Y; Ohno, E; Okusaka, T; Maruki, Y; Kobayashi, S; Ashida, R; Yashika, J; Furuse, J; Ikeda, M; Kasuya, H; Tanaka, M; Hashimoto, Y · Annals of Oncology · 2019